Monoclonal Gammopathy of Renal Significance Relapse-Free Survival Better With Maintenance Therapy Edited by Katie Lennon

https://www.medscape.com/viewarticle/monoclonal-gammopathy-renal-significance-relapse-free-2026a1000o0c?src= Maintenance therapy and treatment duration longer than 6 months are associated with improved relapse-free survival in patients with monoclonal gammopathy of renal significance (MGRS), according to a retrospective analysis of 50 patients. Among patients with a plasma cell clone, median relapse-free survival was not reached with maintenance therapy vs 2.9 years without maintenance.